You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.
